Your session is about to expire
← Back to Search
Capivasertib + Abiraterone for Prostate Cancer (SNARE Trial)
Phase 2
Waitlist Available
Led By Ryan P Kopp, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 months
Awards & highlights
SNARE Trial Summary
This trial tests a drug to shrink/destroy prostate cancer before surgery. It's studied before surgery to see if it's safe and effective.
Who is the study for?
Men over 18 with high-risk, non-metastatic prostate cancer that's not spread beyond the prostate and has specific genetic features (PTEN loss). They should have a life expectancy of more than 10 years, be able to take oral medication, and have no severe health issues. Men must use condoms if with a partner who can bear children. Those with active hepatitis or HIV, other cancers, significant heart disease or recent major surgery aren't eligible.Check my eligibility
What is being tested?
The trial is testing whether taking capivasertib along with intensified hormone therapy drugs (abiraterone acetate and leuprolide) before surgical removal of the prostate can shrink tumors in men whose cancer hasn't spread but is at high risk for progression.See study design
What are the potential side effects?
Possible side effects include hormonal changes leading to hot flashes or sexual dysfunction, digestive issues like nausea or diarrhea from oral medications, potential liver function changes due to drug metabolism, fatigue from treatment intensity and increased risk of infections.
SNARE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Neoplasm, Residual
Secondary outcome measures
ERG Expression and Pathologic Response
Surgical Complications
Other outcome measures
Treatment related adverse events
SNARE Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment2 Interventions
neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capivasertib
2021
Completed Phase 1
~130
abiraterone acetate
2017
Completed Phase 4
~920
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,609 Previous Clinical Trials
3,306,573 Total Patients Enrolled
15 Trials studying Prostate Cancer
8,785 Patients Enrolled for Prostate Cancer
Ryan P Kopp, MDPrincipal InvestigatorVA Portland Health Care System, Portland, OR
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had treatments for prostate cancer, including hormone therapy, radiation, or chemotherapy.I have not had major surgery or a serious injury recently.I have had a bone marrow or organ transplant in the past.I am willing to give a tissue sample for testing.I cannot have a biopsy for research purposes.I do not have any health issues that would stop me from following the study rules.I am scheduled for prostate surgery with lymph node removal.My heart health is stable, with no recent severe issues or uncontrolled blood pressure.I am a man who will use birth control when with a woman who can have children.I haven't had any cancer other than low-risk skin cancer in the past 5 years.My prostate cancer is considered high-risk based on its grade, stage, or PSA levels.I have recently been treated with cancer drugs or monoclonal antibodies.I have discussed treatment options with my doctor and chosen surgery.I am 18 years old or older.My organ functions are within normal ranges according to recent tests.I weigh at least 45 kg and my BMI is at least 18.5.My prostate cancer is confirmed and has not spread.I am fully active or can carry out light work.I can take and keep down pills.I have not taken certain medications recently.
Research Study Groups:
This trial has the following groups:- Group 1: Single Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What safeguards have been implemented to ensure the safety of patients in Single Arm trials?
"Single Arm received a score of 2, indicating that while there is promising safety data associated with it, its efficacy still requires further study."
Answered by AI
Is there still an opportunity to participate in this clinical examination?
"Clinicaltrials.gov indicates that the original posting for this trial, which was last edited on November 7th 2022, is now inactive and not currently recruiting patients. Nevertheless, there are 1247 other medical studies actively enrolling individuals presently."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger